WHAT IS CLAIMED IS:

5

15

20

1. A method of accelerating wound healing, comprising applying to a wound an effective amount to accelerate wound healing of at least one peptide other than Angiotensin II, said peptide consisting essentially of at least three contiguous amino acids and having a sequence corresponding to a subsequence of groups R¹-R⁸ in general formula I:

$$R^{1} - R^{2} - R^{3} - R^{4} - R^{5} - R^{6} - R^{7} - R^{8}$$
 (SEQ ID NO:15), wherein

R¹ is selected from the group consisting of Asp, Glu, Asn, Acpc, Ala, Me²Gly, Pro, Bet, Glu(NH₂), Gly, Asp(NH₂) and Suc;

R² is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

R³ is selected from the group consisting of Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R⁴ is selected from the group consisting of Tyr, Thr, Ser and azaTyr;

R⁵ is selected from the group consisting of Ile, Ala, Leu, Val and Gly;

R⁶ is His or Arg;

R⁷ is Pro or Ala; and

R⁸ is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences wherein R⁴ is an amino terminal Tyr group of the peptide.

- 2. A method according to Claim 1, wherein the peptide is administered in matrical or micellar solution.
- 3. A method according to Claim 1, wherein the peptide is administered in an amount of at least 0.1 ng per kg body weight in a suitable carrier or diluent.
- 4. A method according to Claim 3, wherein the carrier or diluent is selected from the group consisting of carboxymethyl cellulose preparations, crystalloid preparations, viscoelastics, polyethylene glycols and polypropylene glycols.
 - 5. A method according to Claim 1, wherein the peptide is administered in conjunction with a wound dressing.
- 30 6. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^1 R^2 R^3$ in general formula I.

- 7. A method according to Claim 6, wherein the peptide has a sequence consistently essentially of Asp Arg Val (SEO ID NO:11).
- 8. A method according to Claim 1, wherein the peptide has a sequence 5 consisting essentially of R¹ R² R³ R⁴ in general formula I.
 - 9. A method according to Claim 8, wherein the peptide has a sequence consistently essentially of Asp Arg Val Tyr (SEQ ID NO:10).
 - 10. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^1 R^2 R^3 R^4 R^5$ in general formula I.
- 10 11. A method according to Claim 10, wherein the peptide has a sequence consistently essentially of Asp Arg Val Tyr Ile (SEQ ID NO:9).
 - 12. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^1 R^2 R^3 R^4 R^5 R^6$ in general formula I.
- 13. A method according to Claim 12, wherein the peptide has a sequence consistently essentially of Asp Arg Val Tyr Ile His (SEQ ID NO:8).
 - 14. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^3 R^4 R^5 R^6 R^7$ in general formula I.
 - 15. A method according to Claim 14, wherein the peptide has a sequence consistently essentially of Val Tyr Ile His Pro (SEQ ID NO:6).
- 20 16. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^2 R^3 R^4 R^5 R^6 R^7$ in general formula I.
 - 17. A method according to Claim 16, wherein the peptide has a sequence consistently essentially of Arg Val Tyr Ile His Pro (SEQ ID NO:5).
- 18. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^3 R^4 R^5 R^6 R^7 R^8$ in general formula I.
 - 19. A method according to Claim 18, wherein the peptide has a sequence consistently essentially of Val Tyr Ile His Pro Phe (SEQ ID NO:3).
 - 20. A method according to Claim 1, wherein the peptide has a sequence consisting essentially of $R^5 R^6 R^7 R^8$ in general formula I.
- 30 21. A method according to Claim 20, wherein the peptide has a sequence consistently essentially of Ile His Pro Phe (SEQ ID NO:7).

- 22. A method according to Claim 1, wherein the peptide comprises poly-Gly.
- 23. A method according to Claim 22, wherein the peptide has a sequence selected from Asp-Arg-Val-Gly-Gly-Gly-Gly (SEQ ID NO:16) and Gly-Gly-Gly-Asp-Arg-Val (SEQ ID NO:17).
 - 24. A method according to Claim 1, wherein the peptide comprises poly-Lys.
- 25. A method according to Claim 24, wherein the peptide has a sequence selected from Arg-Val-Tyr-Ile-His-Pro-Lys-Lys-Lys (SEQ ID NO:18) and Lys-Lys-Lys-Lys-Lys-Lys-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO:19)
 - 26. A method according to Claim 1, wherein the peptide comprises a D-amino acid.
- 27. A method according to Claim 26, wherein the peptide has a sequence selected from D-Ala-Ile-His-Pro-Phe (SEQ ID NO:20); and Ile-His-Pro-Phe-D-Ala (SEQ ID NO:21)
 - 28. A method according to claim 1, wherein the peptide is PEGylated.
 - 29. A method according to Claim 28, wherein the PEGylated peptide is selected from the peptides of SEQ ID NOS. 3, 5, 6, 7, 8, 9, 10, and 11.